MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-13-2025
Aptose Biosciences Total Non Current Liabilities 2011-2026 | APTO
Annual Total Non Current Liabilities Aptose Biosciences
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 10.2 M | 621 K | - | - | 535 K | 1.01 M | - | - | - | - | 487 K | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 10.2 M | 487 K | 2.57 M |
Quarterly Total Non Current Liabilities Aptose Biosciences
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 18.7 M | 11 M | 8.54 M | 10.2 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 18.7 M | 8.54 M | 12.1 M |
Total Non Current Liabilities of other stocks in the Biotechnology industry
| Issuer | Total Non Current Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
40.2 M | - | 2.43 % | $ 254 M |  Germany |
 |
Alector
ALEC
|
165 M | $ 2.11 | -13.17 % | $ 217 M |  USA |
 |
Acer Therapeutics
ACER
|
244 K | - | 2.71 % | $ 14 M | USA |
 |
Axsome Therapeutics
AXSM
|
48.9 M | $ 163.89 | - | $ 8.15 B | USA |
 |
BridgeBio Pharma
BBIO
|
97.6 M | $ 64.28 | -3.31 % | $ 12.3 B | USA |
 |
I-Mab
IMAB
|
131 M | - | - | $ 866 M |  China |
 |
BioCardia
BCDA
|
1.3 M | $ 1.37 | 5.81 % | $ 29 M | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
4.83 B | - | - | $ 40.3 B | USA |
 |
AgeX Therapeutics
AGE
|
1.53 M | - | -10.17 % | $ 12.2 K | USA |
 |
Biophytis SA
BPTS
|
2.02 M | - | -13.47 % | $ 169 M |  France |
 |
Aeglea BioTherapeutics
AGLE
|
4.74 M | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
4.15 M | - | - | $ 26.5 M | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
6.39 M | - | -1.52 % | $ 24.7 M | USA |
 |
BioLineRx Ltd.
BLRX
|
8.22 M | $ 2.82 | -0.35 % | $ 908 M |  Israel |
 |
Midatech Pharma plc
MTP
|
110 K | - | -18.52 % | $ 27.3 M |  Britain |
 |
BioMarin Pharmaceutical
BMRN
|
635 M | $ 59.8 | -3.13 % | $ 11.5 B | USA |
 |
Bristol-Myers Squibb Company
BMY
|
59.9 B | $ 62.08 | -0.46 % | $ 126 B | USA |
 |
Benitec Biopharma
BNTC
|
213 K | $ 10.93 | 0.23 % | $ 450 M | USA |
 |
BioNTech SE
BNTX
|
341 M | $ 109.33 | -0.82 % | $ 27.2 B | Germany |
 |
Black Diamond Therapeutics
BDTX
|
7.69 M | $ 2.38 | -3.44 % | $ 131 M | USA |
 |
ARCA biopharma
ABIO
|
409 K | - | 1052.0 % | $ 415 M | USA |
 |
Acorda Therapeutics
ACOR
|
257 M | - | -24.86 % | $ 820 K | USA |
 |
BioXcel Therapeutics
BTAI
|
1.4 M | $ 1.63 | -2.4 % | $ 4.13 M | USA |
 |
Acasti Pharma
ACST
|
12.2 M | - | 4.01 % | $ 150 M |  Canada |
 |
Adverum Biotechnologies
ADVM
|
27.3 M | - | - | $ 86.2 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
541 M | - | - | - |  Russia |
 |
AIkido Pharma
AIKI
|
2.29 M | - | 1.93 % | $ 17.4 M | USA |
 |
Akero Therapeutics
AKRO
|
1.52 M | - | - | $ 3.67 B | USA |
 |
Akouos
AKUS
|
12 M | - | 0.23 % | $ 488 M | USA |
 |
BeyondSpring
BYSI
|
37.6 M | $ 1.34 | -0.87 % | $ 54 M | USA |
 |
Albireo Pharma
ALBO
|
79.1 M | - | -0.23 % | $ 916 M | USA |
 |
Allena Pharmaceuticals
ALNA
|
10.2 M | - | 3.16 % | $ 1.9 M | USA |
 |
Cabaletta Bio
CABA
|
43.9 M | $ 3.34 | 0.61 % | $ 3.9 M | USA |
 |
Aileron Therapeutics
ALRN
|
4.59 M | - | 10.36 % | $ 9.8 M | USA |
 |
AlloVir
ALVR
|
5.46 M | - | 4.14 % | $ 49.1 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
1.63 M | $ 4.88 | 2.74 % | $ 10.6 B | Israel |
 |
Alpine Immune Sciences
ALPN
|
15.9 M | - | - | $ 2.17 B | USA |
 |
Capricor Therapeutics
CAPR
|
4.86 M | $ 27.28 | -2.32 % | $ 731 M | USA |
 |
Aeterna Zentaris
AEZS
|
19.1 M | - | 5.93 % | $ 314 M | Canada |
 |
Ampio Pharmaceuticals
AMPE
|
3.53 M | - | -11.43 % | $ 502 K | USA |
 |
Catalyst Biosciences
CBIO
|
981 K | $ 11.67 | -3.47 % | $ 768 M | USA |
 |
Applied Molecular Transport
AMTI
|
106 M | - | - | $ 10.1 M | USA |
 |
Aravive
ARAV
|
10.2 M | - | -13.39 % | $ 1.45 M | USA |
 |
C4 Therapeutics
CCCC
|
75.5 M | $ 3.06 | 13.3 % | $ 254 M | USA |
 |
Aptinyx
APTX
|
114 K | - | -39.0 % | $ 4.57 M | USA |
 |
Athira Pharma
ATHA
|
876 K | - | - | $ 269 M | USA |
 |
Codexis
CDXS
|
28.2 M | $ 0.99 | -2.04 % | $ 72.7 M | USA |
 |
Aridis Pharmaceuticals
ARDS
|
854 K | - | 17.91 % | $ 11.1 M | USA |